Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL-experience of the German Hodgkin's lymphoma study group analyzed by a parametric model of carcinogenesis

Annals of Oncology

Volumn 22, Issue 3, 2011, Pages 681-688

  Scholz, M ^a   Engert, A ^b   Franklin, J ^b   Josting, A ^b   Diehl, V ^b   Hasenclever, D ^a   Loeffler, M ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

BEACOPP escalated; Carcinogenesis model; Hodgkin's lymphoma; Secondary AML MDS; Secondary NHL

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; LOMUSTINE; METHOTREXATE; PREDNISONE; VINBLASTINE; VINCRISTINE; VINDESINE; ANTINEOPLASTIC AGENT; PROCARBAZINE; GLYOXAL; PREDNIMUSTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CARCINOGENESIS; HODGKIN DISEASE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RISK FACTOR; ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CONTROLLED STUDY; MATHEMATICAL MODEL; RISK ASSESSMENT; TREATMENT DURATION; ALGORITHM; CHEMICALLY INDUCED DISORDER; KAPLAN MEIER METHOD; MORTALITY; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECOND CANCER; TREATMENT OUTCOME;

ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; GLYOXAL; HODGKIN DISEASE; HUMANS; IFOSFAMIDE; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; LYMPHOMA, NON-HODGKIN; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY; PREDNIMUSTINE; PREDNISONE; PROCARBAZINE; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; TREATMENT OUTCOME; VINBLASTINE; VINCRISTINE;

EID: 79952032565     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq408     Document Type: Article

References (49)

1. Evens AM, Hutchings M, Diehl V. Treatment of Hodgkin lymphoma: the past, present, and future. Nat Clin Pract Oncol 2008; 5: 543-556.
2. Diehl V, Franklin J, Pfreundschuh M et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348: 2386-2395.
3. Engert A, Diehl V, Franklin J et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's Lymphoma: 10 years of follow-up of the GHSG HD9 Study. J Clin Oncol 2009; 27: 4548-4554.
4. Cosset JM, Henry-Amar M, Meerwaldt JH. Long-term toxicity of early stages of Hodgkin's disease therapy: the EORTC experience. EORTC Lymphoma Cooperative Group. Ann Oncol 1991; 2 (Suppl 2): 77-82.
5. Hirsch A, Vander Els N, Straus DJ et al. Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease. J Clin Oncol 1996; 14: 1297-1305.
6. Horning SJ, Adhikari A, Rizk N et al. Effect of treatment for Hodgkin's disease on pulmonary function: results of a prospective study. J Clin Oncol 1994; 12: 297-305.
7. Kreuser ED, Felsenberg D, Behles C et al. Long-term gonadal dysfunction and its impact on bone mineralization in patients following COPP/ABVD chemotherapy for Hodgkin's disease. Ann Oncol 1992; 3 (Suppl 4): 105-110.
8. Dorr FA, Coltman CA Jr. Second cancers following antineoplastic therapy. Curr Probl Cancer 1985; 9: 1-43.
9. Leone G, Pagano L, Ben-Yehuda D, Voso MT. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica 2007; 92: 1389-1398.
10. Park DJ, Koeffler HP. Therapy-related myelodysplastic syndromes. Semin Hematol 1996; 33: 256-273.
11. Brunning RD, Matutes E, Harris NL et al. Acute myeloid leukemia. In Jaffe ES, Harris NL, Stein H, Vardiman J (eds) World Health Organization of Tumors Pathology and Genetics, Tumors of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press 2001; 75-108.
12. Tucker MA, Coleman CN, Cox RS et al. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 1988; 318: 76-81.
13. Abrahamsen JF, Andersen A, Hannisdal E et al. Second malignancies after treatment of Hodgkin's disease: the influence of treatment, follow-up time, and age. J Clin Oncol 1993; 11: 255-261.
14. van Leeuwen FE, Chorus AM, van den Belt-Dusebout AW et al. Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol 1994; 12: 1063-1073.
15. Shulman LN. The biology of alkylating-agent cellular injury. Hematol Oncol Clin North Am 1993; 7: 325-335.
16. Felix CA. Secondary leukemias induced by topoisomerase-targeted drugs. Biochim Biophys Acta 1998; 1400: 233-255.
17. Pedersen-Bjergaard J, Andersen MK, Christiansen DH, Nerlov C. Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood 2002; 99: 1909-1912.
18. Larson RA, Le Beau MM. Therapy-related myeloid leukaemia: a model for leukemogenesis in humans. Chem Biol Interact 2005; 153-154: 187-195.
19. Franklin JG, Paus MD, Pluetschow A, Specht L. Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk. Cochrane Database Syst Rev 2005; 4, Art.No. CD003187.
20. Franklin J, Pluetschow A, Paus M et al. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. Ann Oncol 2006; 17: 1749-1760.
21. Kaldor JM, Day NE, Clarke EA et al. Leukemia following Hodgkin's disease. N Engl J Med 1990; 322: 7-13.
22. Henry-Amar M. Second cancer after the treatment for Hodgkin's disease: a report from the International Database on Hodgkin's Disease. Ann Oncol 1992; 3 (Suppl 4): 117-128.
23. Brusamolino E, Anselmo AP, Klersy C et al. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher after combined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study. Haematologica 1998; 83: 812-823.
24. Delwail V, Jais JP, Colonna P, Andrieu JM. Fifteen-year secondary leukaemia risk observed in 761 patients with Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy plus high-dose irradiation. Br J Haematol 2002; 118: 189-194.
25. Krikorian JG, Burke JS, Rosenberg SA, Kaplan HS. Occurrence of non-Hodgkin's lymphoma after therapy for Hodgkin's disease. N Engl J Med 1979; 300: 452-458.
26. Mauch PM, Kalish LA, Marcus KC et al. Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long-term analysis of risk factors and outcome. Blood 1996; 87: 3625-3632.
27. Dores GM, Metayer C, Curtis RE et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol 2002; 20: 3484-3494.
28. Bhatia S, Yasui Y, Robison LL et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol 2003; 21: 4386-4394.
29. Swerdlow AJ, Douglas AJ, Hudson GV et al. Risk of second primary cancers after Hodgkin's disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation. BMJ 1992; 304: 1137-1143.
30. Bhatia S, Robison LL, Oberlin O et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 1996; 334: 745-751.
31. Kim H, Hendrickson R, Dorfman RF. Composite lymphoma. Cancer 1977; 40: 959-976.
32. Miettinen M, Franssila KO, Saxen E. Hodgkin's disease, lymphocytic predominance nodular. Increased risk for subsequent non-Hodgkin's lymphomas. Cancer 1983; 51: 2293-2300.
33. Hansmann ML, Stein H, Fellbaum C et al. Nodular paragranuloma can transform into high-grade malignant lymphoma of B type. Hum Pathol 1989; 20: 1169-1175.
34. Bennett MH, MacLennan KA, Vaughan Hudson G, Vaughan Hudson B. Non-Hodgkin's lymphoma arising in patients treated for Hodgkin's disease in the BNLI: a 20-year experience. British National Lymphoma Investigation. Ann Oncol 1991; 2 (Suppl 2): 83-92.
35. Amini RM, Enblad G, Sundstrom C, Glimelius B. Patients suffering from both Hodgkin's disease and non-Hodgkin's lymphoma: a clinico-pathological and immuno-histochemical population-based study of 32 patients. Int J Cancer 1997; 71: 510-516.
36. Doll R. Radiation hazards: 25 years of collaborative research. Sylvanus Thompson memorial lecture, April 1980. Br J Radiol 1981; 54: 179-186.
37. Krishnan B, Morgan GJ. Non-Hodgkin lymphoma secondary to cancer chemotherapy. Cancer Epidemiol Biomarkers Prev 2007; 16: 377-380.
38. Kaldor JM, Day NE, Band P et al. Second malignancies following testicular cancer, ovarian cancer and Hodgkin's disease: an international collaborative study among cancer registries. Int J Cancer 1987; 39: 571-585.
39. Dietrich PY, Henry-Amar M, Cosset JM et al. Second primary cancers in patients continuously disease-free from Hodgkin's disease: a protective role for the spleen? Blood 1994; 84: 1209-1215.
40. Enrici RM, Anselmo AP, Iacari V et al. The risk of non-Hodgkin's lymphoma after Hodgkin's disease, with special reference to splenic treatment. Haematologica 1998; 83: 636-644.
41. van Leeuwen FE, Klokman WJ, Hagenbeek A et al. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. J Clin Oncol 1994; 12: 312-325.
42. Yakovlev A, Tsodikov AD. Stochastic Models of Tumor Latency and Their Biostatistical Applications. Singapore: World Scientific Publishing Co. 1996.
43. Tsodikov A, Loeffler M, Yakovlev A. A cure model with time-changing risk factor: an application to the analysis of secondary leukaemia. A report from the International Database on Hodgkin's Disease. Stat Med 1998; 17: 27-40.
44. Josting A, Wiedenmann S, Franklin J et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003; 21: 3440-3446.
45. Rueffer U, Josting A, Franklin J et al. Non-Hodgkin's lymphoma after primary Hodgkin's disease in the German Hodgkin's Lymphoma Study Group: incidence, treatment, and prognosis. J Clin Oncol 2001; 19: 2026-2032.
46. Behringer K, Diehl V. Twenty-five years clinical trials of the German Hodgkin Study Group (GHSG). Eur J Haematol Suppl 2005; 66: 21-25.
47. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr 1974; 19: 716-723.
48. Ihaka R, Gentleman R. R a language for data analysis and graphics. J Comp Graph Stat 1996; 5: 299-314.
49. Blayney DW, Longo DL, Young RC et al. Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease. N Engl J Med 1987; 316: 710-714.